FUSN

Fusion Pharmaceuticals Inc. (FUSN) | Rumor.io

Fusion Pharmaceuticals

FUSN

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about FUSN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% 0

Apr 7

$FUSN is considered a promising investment opportunity with a bright future, according to some analysts.
The company's project is seen as innovative and too perfect to be true, leading to bullish sentiments.
Many users are enthusiastic about the potential of $FUSN to moon, with some even sharing wallet addresses to participate in airdrops and giveaways.

Generated by AI

Sentiment

Of the messages about FUSN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100% +32.14
Bearish	—	—	—	0% -32.14

Bullish· Mar 19

Fusion Pharmaceuticals Inc. (FUSN) saw a 97% increase after being acquired by AstraZeneca for $2.4B in cash.
Long-term investors in FUSN were rewarded with significant gains, with some investors experiencing a 10-bagger return in just half a year.
The acquisition of FUSN by AstraZeneca is seen as a positive indicator for other biotech companies, with potential for similar jumps in value, such as $TRIL and $BLU.

Bearish· Mar 19

The short interest in $FUSN is high, with over 18% of the float shorted, potentially leading to a short squeeze.
The company's market dynamics may be influenced by institutional investors, who could be looking to offload shares to retail holders, as seen in the comparison with $ATNM.
The $FUSN short squeeze is already underway, with bears facing a brutal outcome, and the market is anticipating a significant deterioration in the stock's price in the near future.

Generated by AI

Topics

Of the messages about FUSN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	100%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0%

Mar 20

AstraZeneca has agreed to acquire Fusion Pharmaceuticals in a $2B deal, with Fusion Pharmaceuticals' shares soaring 97% on the news.
Fusion Pharmaceuticals has reported its fourth quarter and full year 2023 financial results, with the company expecting its cash to be sufficient to fund operations into 2025.
Fusion Pharmaceuticals has announced clinical program updates, including the initiation of the Phase 2 portion of the registrational program for its lead program, FPI-2265, in metastatic castration-resistant prostate cancer.

Generated by AI

Community

Of the messages about FUSN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	7%
Newcomers	—	—	—	93%

Regulars· Mar 19

$FUSN is being acquired by $AZN for $21.00/shr in cash at closing, plus a non-transferrable CVR of $3.00/shr in a $2.4B deal.
The acquisition is seen as accelerating the development of next-generation radioconjugates to treat cancer, building on the companies' 2020 deal focused on MAbs.
The regulars are congratulating long-term investors who held through drawdowns, with some pointing out that the stock has had a significant turnaround, from $2 52-week lows to $20+ 52-week highs.

Newcomers· Mar 20

The company's high volume and 794% spike in price have made waves in the healthcare industry, with many users discussing its potential for huge returns.
AstraZeneca is acquiring Fusion Pharmaceuticals in a $2B deal, which is a significant development for the company.
Perceptive Advisors has been actively investing in Fusion Pharmaceuticals, with a recent purchase of 1.9 million shares and a total position of 4.7 million shares.

Generated by AI

Also Discussed

Investors talking about FUSN also mention

#	Name	Attention
1	DAWN - Day One Biopharmaceuticals, Inc.	——
2	LABP - Landos Biopharma, Inc.	——
3	PSTX - Poseida Therapeutics, Inc.	——
4	Novartis AG Sponsored ADRNVS	0%-0.01
5	AVRO - AVROBIO, Inc.	——
6	YMAB - Y-mAbs Therapeutics, Inc.	——
7	ICVX - Icosavax, Inc.	——
8	RPTX - Repare Therapeutics Inc.	——
9	Zymeworks Inc.ZYME	0%0
10	RYZB - RayzeBio, Inc. Common Stock	——